OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Conditions
- Significant Bleeding RiskVitamin K-Dependent Coagulation Defect
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 3574
- Registration Number
- NCT06429787
- Locations
- 🇺🇸
Octapharma Research Site, Boston, Massachusetts, United States
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- Conditions
- Acquired Antithrombin Deficiency (Heparin Resistance)
- Interventions
- Drug: Human plasma derived antithrombinDrug: Placebo
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Octapharma AG
- Target Recruit Count
- 58
- Registration Number
- 2023-507560-39-00
- Locations
- 🇦🇹
Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Medical University of Vienna, AKH, Vienna, Austria
🇷🇴Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu, Bucharest, Romania
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05936580
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇫🇮Helsinki University Hospital,Coagulation Disorder Unit, Helsinki, Finland
🇫🇷Avenue de la République, Chambray-lès-Tours, France
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05935358
- Locations
- 🇮🇳
St. John's Medical College Hospital, Bengaluru, India
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇭🇷University Hospital Centre Zagreb, Zagreb, Croatia
Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
- Conditions
- Bleeding Cardiac Surgery Patients
- Interventions
- Drug: Frozen Plasma Product, Human
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 419
- Registration Number
- NCT05523297
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇨🇦Royal Columbian Hospital, New Westminster, British Columbia, Canada
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 12
- Registration Number
- NCT04953884
- Locations
- 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇨🇿University Hospital Ostrava Department for Pediatric Medicine, Ostrava, Czechia
🇨🇿University Hospital Motol, Department of Paediatric Haematology and Oncology, Prague, Czechia
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
- Conditions
- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 30
- Registration Number
- NCT04929236
- Locations
- 🇺🇸
Octapharma Research Site, Charlottesville, Virginia, United States
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 38
- Registration Number
- NCT04918173
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇨🇿Centre for Thrombosis and Haemaostasis, Nymburk, Czechia
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 260
- Registration Number
- NCT04867837
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸The University of Florida, Gainesville, Florida, United States
🇺🇸St. Mary's Medical Center, West Palm Beach, Florida, United States